Logo image of MAIA

MAIA BIOTECHNOLOGY INC (MAIA) Stock Fundamental Analysis

NYSEARCA:MAIA - NYSE Arca - US5526411021 - Common Stock - Currency: USD

1.85  -0.05 (-2.63%)

After market: 1.8101 -0.04 (-2.16%)

Fundamental Rating

2

Overall MAIA gets a fundamental rating of 2 out of 10. We evaluated MAIA against 571 industry peers in the Biotechnology industry. The financial health of MAIA is average, but there are quite some concerns on its profitability. MAIA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MAIA has reported negative net income.
MAIA had a negative operating cash flow in the past year.
In the past 5 years MAIA always reported negative net income.
In the past 5 years MAIA always reported negative operating cash flow.
MAIA Yearly Net Income VS EBIT VS OCF VS FCFMAIA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -280.64%, MAIA is doing worse than 94.32% of the companies in the same industry.
MAIA's Return On Equity of -1602.59% is on the low side compared to the rest of the industry. MAIA is outperformed by 84.90% of its industry peers.
Industry RankSector Rank
ROA -280.64%
ROE -1602.59%
ROIC N/A
ROA(3y)-168.87%
ROA(5y)-353.99%
ROE(3y)-1489.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAIA Yearly ROA, ROE, ROICMAIA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 2K -2K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MAIA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MAIA Yearly Profit, Operating, Gross MarginsMAIA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

MAIA has more shares outstanding than it did 1 year ago.
There is no outstanding debt for MAIA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MAIA Yearly Shares OutstandingMAIA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M
MAIA Yearly Total Debt VS Total AssetsMAIA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -14.68, we must say that MAIA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MAIA (-14.68) is worse than 81.71% of its industry peers.
MAIA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.68
ROIC/WACCN/A
WACCN/A
MAIA Yearly LT Debt VS Equity VS FCFMAIA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

MAIA has a Current Ratio of 2.56. This indicates that MAIA is financially healthy and has no problem in meeting its short term obligations.
MAIA's Current ratio of 2.56 is on the low side compared to the rest of the industry. MAIA is outperformed by 71.40% of its industry peers.
MAIA has a Quick Ratio of 2.56. This indicates that MAIA is financially healthy and has no problem in meeting its short term obligations.
MAIA has a worse Quick ratio (2.56) than 70.16% of its industry peers.
Industry RankSector Rank
Current Ratio 2.56
Quick Ratio 2.56
MAIA Yearly Current Assets VS Current LiabilitesMAIA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

MAIA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.87%, which is quite good.
EPS 1Y (TTM)9.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MAIA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 68.92% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.21%
EPS Next 2Y3.72%
EPS Next 3Y-10.86%
EPS Next 5Y68.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MAIA Yearly Revenue VS EstimatesMAIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
MAIA Yearly EPS VS EstimatesMAIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MAIA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MAIA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAIA Price Earnings VS Forward Price EarningsMAIA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MAIA Per share dataMAIA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as MAIA's earnings are expected to decrease with -10.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.72%
EPS Next 3Y-10.86%

More info and screens

0

5. Dividend

5.1 Amount

MAIA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAIA BIOTECHNOLOGY INC

NYSEARCA:MAIA (2/21/2025, 8:04:02 PM)

After market: 1.8101 -0.04 (-2.16%)

1.85

-0.05 (-2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners5.29%
Inst Owner Change-5.74%
Ins Owners16.08%
Ins Owner Change2.2%
Market Cap48.40M
Analysts82.86
Price Target14.28 (671.89%)
Short Float %3.08%
Short Ratio1.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)39.1%
Min EPS beat(2)5.5%
Max EPS beat(2)72.7%
EPS beat(4)2
Avg EPS beat(4)15.5%
Min EPS beat(4)-15.64%
Max EPS beat(4)72.7%
EPS beat(8)5
Avg EPS beat(8)10.67%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.89%
PT rev (3m)10.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.58%
EPS NY rev (3m)-1.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 29.9
P/tB 29.9
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -280.64%
ROE -1602.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-168.87%
ROA(5y)-353.99%
ROE(3y)-1489.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.56
Quick Ratio 2.56
Altman-Z -14.68
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.44%
EPS Next Y-10.21%
EPS Next 2Y3.72%
EPS Next 3Y-10.86%
EPS Next 5Y68.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-54.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-46.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.82%
OCF growth 3YN/A
OCF growth 5YN/A